Vered Rosenberg

Ms. Vered Rosenberg

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
VRVered Rosenberg
Vered Rosenberg
Gabriel ChodickGabriel Chodick
Gabriel Chodick
ZXZhenyi Xue
Zhenyi Xue
FFFreddy Jose Faccin
Freddy Jose Faccin
HAHoward AMITAL
Howard AMITAL
Introduction Biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are important treatments for rheumatoid arthritis (RA). As more of these drugs become available, there is a greater need to assess their real-world adherence and drug survival. Methods Treatment-naïve and treatment-experienced patients with RA who initiated treatment with bDMARDs and tofactinib during 2015–2018 in a large Israeli health maintenance organization were included. Adherence and time to treatment suspension were recorded. Odds for adherence were estimated using a multivariable logistic regression model. Risk for treatment suspension was estimated using a mixed-effect Cox proportional hazard model. Results The analysis included 753 eligible patients (61.8% treatment-naïve) treated with 1287 treatment episodes (tofacitinib 24.2%, tocilizumab 17.5%, etanercept 16.0%, adalimumab 10.4%, abatacept 9.9%, rituximab 9.0%, golimumab 6.9%, certolizumab pegol 3.6%, infliximab 1.9%, and sarilumab 0.5%). Good adherence was measured for almost all drugs, yet over 50% of all treatment episodes were suspended. Older age was associated with reduced risk for treatment suspension while higher number of primary care visits and higher Charlson’s comorbidity score were associated with increased risk. Compared to etanercept, treatment with adalimumab, certolizumab, or rituximab was associated with increased risk for treatment suspension (HR 1.68 95% CI 1.27–2.22, HR 1.62 95% CI 1.00–2.60, and HR 2.72 95% CI 2.02–3.67, respectively). Conclusion Treatment choice primarily depends on disease activity and prognosis. Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy.

Verified
Journal Article
Open access
PDF file
VRVered Rosenberg
Vered Rosenberg
HAHoward AMITAL
Howard AMITAL
Gabriel ChodickGabriel Chodick
Gabriel Chodick
FFFreddy Jose Faccin
Freddy Jose Faccin
Abdulla WatadAbdulla Watad
Abdulla Watad
OGOmer Gendelman
Omer Gendelman
Objectives: The objective of this study was to evaluate the real-world drug survival, adherence, and discontinuation risk of biologics disease-modifying anti-rheumatic drugs (bDMARDs) among patients with ankylosing spondylitis (AS). Methods: This was a retrospective study using a computerized database. Biologic-naïve and biologic-experienced AS patients who initiated treatment with bDMARDs (tumor necrosis factor alpha inhibitors {TNF-αis} or interleukin-17 inhibitor {IL-17i}) during 2015–2018 were included. Adherence was assessed using the proportion of days covered (PDC) method. Drug survival was analyzed using Kaplan–Meier estimates. Risk of discontinuation was estimated by the Cox proportional hazard model. Results: We identified 343 eligible patients utilizing 481 lines of therapy. The mean age was 44.6 years (SD ± 13.4), 57.7% were males, and 69.7% were biologic-naïve at baseline. The proportion of highly adherent patients (PDC ≥ 0.8) in the biologic-naïve group was 63.5% for golimumab, 69.2% for etanercept, and 71.6% for adalimumab (p > 0.9). Among the biologic-experienced group, secukinumab had the highest proportion of adherent patients (75.7%) and etanercept the lowest (50.0%) reaching statistical difference (p < 0.001). The Kaplan–Meier analysis did not show a significant difference in drug survival in either the biologic-naïve or the biologic-experienced groups (p = 0.85). Multivariable analysis demonstrated a similar risk for discontinuation for etanercept, golimumab, and secukinumab compared with adalimumab, regardless of biologic-experience status. Conclusions: Adherence, drug survival, and risk for discontinuation were similar for all TNF-αis and the IL-17i SEC, regardless of biologic-experience status. As drug survival is an indirect measure of drug efficacy, n, in real-world settings, we believe caregivers can integrate these results into treatment considerations.

6 August 2024 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
VRVered Rosenberg
Vered Rosenberg
HAHoward Amital
Howard Amital
GCGabriel Chodick
Gabriel Chodick
FFFreddy Faccin
Freddy Faccin
OGOmer Gendelman
Omer Gendelman
Background While the variety of biologics (b) and targeted synthetic (ts) disease-modifying anti-rheumatic drugs (DMARDs) available for patients with psoriatic arthritis (PsA) has proved to be efficacious in randomized clinical trials, there is a growing importance to understand the benefits and potential drawbacks of these different therapies in real-world settings, which includes bio-experienced and older patients as well. Objective To evaluate the real-world adherence, drug survival, and discontinuation risk of bDMARDs and tsDMARDs among patients with PsA, comprising both younger and older patients. Methods A retrospective study using a computerized database. Treatment-naïve and treatment-experiencedpatients with PsA, younger and older than 60 years, who initiated treatment with bDMARDs [TNF-α inhibitors (TNF-αis), IL-17 inhibitors (IL-17is), IL-12/23 inhibitors (IL-12/23i)] or tsDMARDs (the PDE-4 inhibitor apremilast) during 2015–2018 were included. Adherence was assessed using the proportion of days covered (PDC) method. Time to discontinuation was analyzed using Kaplan–Meier estimates. Risk of discontinuation was estimated by Cox proportional hazard model. Results We identified 427 eligible patients (22.2 % were older than 60 years), utilizing 673 treatment lines. The proportion of adherent patients (PDC ≥ 0.8) was similar (62.1–66.5%) across all lines of therapy and across different biologics (70.0–72.0%), while apremilast showed the lowest, in both treatment-naïve and experienced settings (43.6% and 25.5%, respectively). The Kaplan–Meier analysis showed that in the treatment-naïve TNF-αis had higher drug survival compared with apremilast (P = 0.032). Apremilast also had the lowest drug survival in the treatment-experienced group (P < 0.0001). Kaplan–Meier analysis by age groups showed similar drug survival rates in older (≥ 60 years) and younger (age < 60 years) patients, regardless of treatment-experience status. The multivariable model showed that apremilast had increased risk for discontinuation compared with TNF-αis. Conclusion Adherence, drug survival and risk for discontinuation were similar for all included bDMARDs, regardless of treatment experience status, while apremilast showed lower rates and increased risk. Adherence and discontinuation rate were similar in older and younger patients. With the variety of drug modes of action available for patients with PsA, these findings may assist caregivers in selecting the appropriate treatment.

1 June 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MNMe Naffaa
Me Naffaa
VRVered Rosenberg
Vered Rosenberg
GCG Chodick
G Chodick
VSV Shalev
V Shalev
STShmuel Tiosano
Shmuel Tiosano
HAHoward AMITAL
Howard AMITAL
Background Several studies have suggested that metformin, an oral hypoglycemic agent, possess an anti-inflammatory property and may have a role in the treatment of rheumatoid arthritis (RA)1,2, but little is known on its preventive effects. Objectives To examine the association between persistence with metformin and the onset of RA. Methods Using the computerized medical database of a large health organization in Israel (Maccabi Healthcare Services, MHS) we have identified incident RA cases among new users of metformin between 1998 and 2014. Included were patients aged 18 or above with one year of follow up before and after the therapy initiation. RA was defined according to physician diagnoses. Participants were followed until the earliest of the following dates: onset of RA, leaving MHS, death, end of follow up (1.1.2016). Persistence with metformin was assessed by calculating the mean proportion of follow-up days covered (PDC) with metformin during the study period. Results A total of 113,749 eligible patients were included. During the study follow up period (794,386 person-years) we identified 600 incident cases (incidence rate of 75 cases per 100,000 PY). The incidence of RA in women (111 per 100,000 PY) was higher compared to men (42 per 100,000 PY). In a multivariable model, persistence with metformin (PDC≥80%) was associated with lower risk of RA (hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.53–0.82) compared to non-persistent participants (PDC<20%). Figure 1 shows the hazard function according to persistence with metformin treatment. Similar risk reduction was observed among men but did not reach statistical significance (HR=0.85; 95% CI 0.54–1.32). Conclusions In the present study, we observed an association between high persistence to metformin therapy and reduced risk of developing RA in women. Disclosure of Interest None declared

20 February 2026 in Respiratory Medicine
Verified
Journal Article
Closed access
VRVered Rosenberg
Vered Rosenberg
RYRoni Yahalom
Roni Yahalom
ILIdit Livnat
Idit Livnat
AYAdva Yarden
Adva Yarden
SGSivan Gazit
Sivan Gazit
NBNeville Berkman
Neville Berkman